Clinical trial
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
NCT00379080 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00379080 |
|---|---|
| Title | Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma |
| Official title | A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients With Recurrent Glioblastoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Adult Brain Tumor, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor |
| Intervention type | Drug, Other, Procedure |
| Interventions | conventional surgery, tandutinib, pharmacological study, Tissue samples |
| Enrollment | 60 |
| Start date | Jan 1, 2007 |
| Primary completion | Sep 1, 2012 |
| Completion | Jun 1, 2013 |
| First posted | Sep 21, 2006 |
| Last update posted | Apr 7, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: